LI FANG,Wang hui qin,HALILOVIC ENSAR,LIANG JINSHENG
申请号：
IN201617015417
公开号：
IN201617015417A
申请日:
2016.05.03
申请国别(地区):
IN
年份:
2016
代理人:
摘要：
A pharmaceutical combination comprising (a) an ALK inhibitor or a pharmaceutically acceptable salt thereof and (b) at least one HDMA 2/p53 receptor inhibitor or a pharmaceutically acceptable salt or at least one BRaf inhibitor or a pharmaceutically acceptable salt and optionally a pharmaceutically acceptable carrier for simultaneous separate or sequential administration； the uses of such combination in the treatment of cancer； and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
